Pharmafile Logo
Pharmafocus logo
Advanced Search

Medical Communications

Showing 15 posts of 6408 posts found.

hal-gatewood-_jbclosdsd4-unsplash

FDA grants ODD to NXC-201 as multiple myeloma treatment

August 24, 2023 Medical Communications FDA, Nexcella, ODD, Oncology, multiple myeloma

Nexcella has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to NXC-201 for …
News
lungs

Daiichi Sankyo’s Enhertu approved in Japan as treatment for metastatic NSCLC

August 23, 2023 Medical Communications Daiichi Sankyo, Enhertu, Japan's MHLW, NSCLC, Oncology, trastuzumab deruxtecan

Daiichi Sankyo has announced that Enhertu (trastuzumab deruxtecan) has been approved in Japan for the treatment of adult patients with …
News

AstraZeneca’s Forxiga approved in China for chronic heart failure treatment

August 18, 2023 Medical Communications AstraZeneca, Cardiology, China, cardiovascular, heart failure

AstraZeneca has announced that Forxiga (dapagliflozin) has been approved in China to reduce the risk of cardiovascular death, hospitalisation for …
News

Iveric Bio’s marketing authorisation application for avacincaptad pegol accepted by EMA

August 18, 2023 Medical Communications CHMP, EMA, Iveric Bio, MAA, Opthalmology

Astellas Pharma has announced that the European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) for avacincaptad pegol …
News

Amicus Therapeutics’ Pompe disease treatment approved for use in UK

August 17, 2023 Medical Communications Amicus Therapeutics, MHRA, NICE, Pompe disease, Rare Diseases

Amicus Therapeutics has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorisation …
News

FDA approved Ipsen’s Sohonos capsules for treatment of fibrodysplasia ossificans progressiva

August 17, 2023 Medical Communications FDA, FOP, Musculo-skeletal disorder, Sohonos, ipsen

Ipsen has announced that the US Food and Drug Administration (FDA) has approved Sohonos (palovarotene) capsules as a retinoid indicated …
News

FDA grants accelerated approval to Pfizer’s Elrexfio

August 15, 2023 Medical Communications Elrexfio, FDA, Oncology, Pfizer, accelerated approval

Pfizer has that the US Food and Drug Administration (FDA) has granted accelerated approval to Elrexfio (elranatamab-bcmm) for the treatment …
News
lungs

FDA grants orphan drug designation to Genprex’s Reqorsa

August 15, 2023 Medical Communications FDA, ODD, Oncology, Reqorsa

Gene therapy company Genprex has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) …
News
pawel-czerwinski-2y8ol_obs1i-unsplash_2

FDA approves Talvey for the treatment of heavily pretreated multiple myeloma

August 11, 2023 Medical Communications FDA, J&J, Janssen, Oncology, Talvey, multiple myeloma

The Janssen Pharmaceutical companies of Johnson & Johnson has announced that the US Food and Drug Administration (FDA) has granted …
News
eye_2

Regeneron shares two-year PULSAR trial results for wAMD

August 11, 2023 Medical Communications Opthalmology, PULSAR trial, Regeneron, wAMD

Regeneron Pharmaceuticals have announced positive, two-year, topline results from its PULSAR trial assessing aflibercept 8mg for the treatment of patients …
News
eye2

Astellas announces FDA approval for Izervay for GA treatment

August 7, 2023 Medical Communications AMD, Astellas Pharma, FDA, Izervay, Opthalmology, geographic atrophy

Astellas Pharma has announced that the US Food and Drug Administration (FDA) has approved Izervay (avacincaptag pegol intravitreal solution) for …
News

FDA approves Taiho’s Lonsurf for metastatic colorectal cancer treatment

August 3, 2023 Medical Communications FDA, Lonsurf, Oncology, colorectal cancer, mCRC, taiho

Taiho Oncology and Taiho Pharmaceutical have announced that the US Food and Drug Administration (FDA) has approved Lonsurf (trifluridine/tipiracil) as …
News
Chemotherapy

FDA grants ODD to ABM Therapeutics’ treatment for patients with glioblastoma

August 3, 2023 Medical Communications ABM Therapeutics, ABM-1310, FDA, Oncology, glioblastoma

ABM Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ABM-1310. …
News

FDA approves a second OTC naloxone nasal spray

July 31, 2023 Medical Communications FDA, Nasal Spray, OTC, OTC Products, naloxone, opioids

The US Food and Drug Administration (FDA) has announced that it has approved RiVive, 3mg naloxone hydrochloride nasal spray for …
News
vaccinessssssssssssssssssss_1

Bavarian Nordic announces RSV vaccine did not meet all primary endpoints in phase 3 trial

July 25, 2023 Medical Communications Bavarian Nordic, Infections and infestations, RSV, Vaccine, clinical trial

Bavarian Nordic has announced that its phase 3 clinical trial of MVA-BN, its respiratory syncytial virus (RSV) vaccine candidate for …
News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026